Ciara Freeman, MD, PhD, discusses anito-cel's unique functions and benefits for treating multiple myeloma. In an interview with Targeted Oncology TM, Ciara Freeman, MD, medical oncologist at Moffitt ...

After treatment with CAR-T cells—immune cells engineered to attack cancer—patients sometimes tell their doctors they feel ...

Over 80% of patients with relapsed/refractory multiple myeloma responded to anti-GPRC5D CAR T-cell therapy after failure of anti-BCMA CAR T-cell therapy. The investigational therapy showed ...

Image Credit: Norgen Biotek Corp. RNA therapeutics and CAR T-cell therapy for the treatment of multiple myeloma Conventional ... and automation-ready magnetic bead-based formats.

Johnson & Johnson and partner Legend Biotech are celebrating a big win in their efforts to expand the use of CAR-T therapy Carvykti for multiple myeloma, after showing a survival benefit in a ...

Sidana specializes in the treatment of multiple myeloma and related disorders and is an associate professor of Medicine at Stanford University, in Stanford, where she also leads the Myeloma ...

The ability to eliminate specific pathologic cells is creating more options for multiple myeloma patients ... chimeric antigen receptor (CAR) T cells have the longest history of clinical development.

More than 80% of patients whose multiple myeloma had progressed on standard chimeric antigen receptor (CAR) T-cell therapy responded to an investigational CAR T-cell agent, a small study from ...